Guidelines on the diagnosis and investigation of AL amyloidosis

Gillmore, Julian D.; Wechalekar, Ashutosh; Bird, Jenny; Cavenagh, Jamie; Hawkins, S.J.; Kazmi, Majid; Lachmann, HJ; Hawkins, Philip N.; Pratt, Guy

doi:10.1111/bjh.13156

Cited by 132 publications

(137 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Valvular defects (mitral and tricuspid insufficiency) are relatively frequent with infiltration of the valvular and suspensory system. Chronic refractory cardiac failure and sudden death due to electromechanical dissociation or arrhythmogenic states are among the most frequent causes of death 7,8,[16][17][18][19][20][21][22][23] . A thorough physical examination may indicate the possible presence of amyloidosis.…”

Section: Clinical Symptoms and Diagnosticsmentioning

confidence: 99%

Amyloid cardiomyopathy

Karafiátová¹,

Pika²

2017

BIOMED PAP

View full text Add to dashboard Cite

Section: Clinical Symptoms and Diagnosticsmentioning

confidence: 99%

Amyloid cardiomyopathy

Karafiátová¹,

Pika²

2017

BIOMED PAP

View full text Add to dashboard Cite

“…56, 76 As mentioned earlier, 11-1F4 conjugated to 124 I can image noncardiac amyloid. 55 The most promising is florbetapir, which has recently been approved by the US Food and Drug Administration for imaging Alzheimer's disease.…”

mentioning

confidence: 90%

Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis

Weiss

Wong

Comenzo

2016

Blood

View full text Add to dashboard Cite

Systemic immunoglobulin light chain (LC) amyloidosis (AL) is a potentially fatal disease caused by immunoglobulin LC produced by clonal plasma cells. These LC form both toxic oligomers and amyloid deposits disrupting vital organ function. Despite reduction of LC by chemotherapy, the restoration of organ function is highly variable and often incomplete. Organ damage remains the major source of mortality and morbidity in AL. This review focuses on the challenges posed by emerging therapies that may limit the toxicity of LC and improve organ function by accelerating the resorption of amyloid deposits.

show abstract

“…A kórkép plazmasejt-dyscrasia talaján alakul ki, lehet önálló entitás, de társulhat myeloma multiplexhez (MM) és ritka esetekben Waldenström-macroglobulinaemiához vagy non-Hodgkin-lymphomához is [1,2]. Különböző szervekben lerakódva az amyloid funkciókárosodást hoz létre, amelynek következménye progresszív szervelégte-lenség.…”

unclassified

“…Különböző szervekben lerakódva az amyloid funkciókárosodást hoz létre, amelynek következménye progresszív szervelégte-lenség. Jellemzően vese-, szív-és májérintettséggel talál-kozunk [2,3].…”

unclassified

See 1 more Smart Citation

Prognosztikai tényezők könnyűlánc-amyloidosisban

et al. 2015

View full text Add to dashboard Cite

Bevezetés: A könnyűlánc-amyloidosis immunglobulinok könnyűláncaiból származó fi brilláris anyag extracelluláris lerakódása következtében kialakuló kórkép. Célkitűzés: A szerzők célja a szívérintettség, a kezelés és a myeloma fennál-lásának függvényében a túlélési idők meghatározása. Prognostic factors in light chain amyloidosisIntroduction: Light chain amyloidosis is characterized by extracellular deposition of a fi brillar material derived from immunglobulin light chain fragments. Aim: The aim of the authors was to assess survival depending on cardiac involvement, therapy, and presence of myeloma. Method: The authors studied a retrospective cohort of 29 patients with light chain amyloidosis (13 kappa, 16 lambda) treated in their institution between 2005 and 2014. Results: Twentyone patients had primary amyloidosis, while 8 had coexisting multiple myeloma. One, two and three or more organs were involved in 4, 8, and 17 patients, respectively. Cardiac involvement (22 cases) inversely correlated with survival. Fifteen (52%) patients received chemotherapy only, while 14 (48%) underwent autologous stem cell transplantation with a median survival of 87 and 11.4 months, respectively. Two patients had heart transplantation and survived 70 and 30 months. Median overall survival was 75.8 months. Conclusions: Cardiac transplantation followed by autologous stem cell transplantation is feasible in selected patients with light chain amyloidosis and heart failure.

show abstract

Guidelines on the diagnosis and investigation of AL amyloidosis

Cited by 132 publications

References 57 publications

Amyloid cardiomyopathy

Amyloid cardiomyopathy

Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis

Prognosztikai tényezők könnyűlánc-amyloidosisban

Contact Info

Product

Resources

About